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Abstract
The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. To reduce the disease 
risk and burden at the population level, preventative strategies should be developed with minimal 
cost and effort and with no side-effects. Low-grade inflammation resulting from imbalances in the 
innate immune system has been associated with an array of chronic disorders that predispose to 
the later development of T2DM (e.g., obesity, metabolic syndrome, and insulin resistance). As a 
result, inflammation may contribute to the pathogenesis of T2DM. Therefore, attenuation of this 
inflammatory response via modulating the innate immune system could lead to improved insu-
lin sensitivity and delayed disease onset. Dietary supplementation with vitamin D may represent a 
novel strategy toward the prevention and control of T2DM at the population level due to its anti-
inflammatory and antioxidant properties. This review examines current knowledge linking T2DM 
to chronic low-grade inflammation and the role of vitamin D in modulating this relationship. The 
concept that vitamin D, via attenuating inflammation, could be employed as a novel preventive me-
asure for T2DM is evaluated in the context of its relevance to health care and public health practices.
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Introduction
Type 2 diabetes mellitus (T2DM) represents a significant global health problem. It is estimated that 
about six people die every minute from the disease worldwide, a figure that will soon make T2DM 
one of the world’s most prevalent health problems [1]. T2DM is associated with increased morbidity 
(blindness, renal failure, amputation) and mortality, and it is a risk factor for cardiovascular disease 
(CVD) and stroke. T2DM depletes significant proportion of the healthcare system resources both in 
the developed and developing countries, an issue that is expected to further exacerbate over the next 
two decades [2]. Risk factors for T2DM include age ≥ 40 years, obesity, ethnicity, genetics, diet and 
physical activity [3]. Drug therapy and lifestyle interventions such as weight loss, diet and exercise are 
traditional strategies for prevention and treatment of T2DM. However, adherence to lifestyle changes 
is difficult for many individuals, and the high cost of treatment poses a large financial burden on the 
health care system. Therefore, there is a need to develop novel approaches for interventions that can be 
implemented at the population level and targeted towards “at-risk” sub-populations, with maximum 
efficacy and minimal financial cost.
T2DM is a progressive chronic disease characterized by insulin resistance and β-cell dysfunction. Insu-
lin resistance is defined as the inability of skeletal muscle, liver and adipose tissue to respond adequately 
to the body’s endogenous insulin secretions. In addition to insulin resistance, β-cell dysfunction plays 
an integral role in the pathogenesis of T2DM. In healthy individuals, the β-cells are able to counte-
ract insulin resistance by increasing insulin production and secretion [4]. Glucose sensors located on 
β-cells sense increases in blood glucose levels despite increases in insulin secretion; this persistent 
hyperglycemia triggers a series of events which ultimately leads to an increase in β-cell expression, 
β-cell mass and enhanced secretory capacity of the pancreas. However, in individuals with T2DM this 
increase in β-cell mass and secretory capacity is disrupted [5].
There is growing evidence that abnormal innate immune responses and chronic low-grade inflamma-
tion play a key role in the pathogenesis of insulin resistance and T2DM [6-10]. Inflammation results 
from the activation of the innate immune response: the body’s immediate, non-specific reaction against 
environmental insults such as pathogens, chemical or physical injury. Inflammation plays a role in 
tissue damage prevention, restoration of tissue homeostasis and destruction of infectious agents [11]. 
It is the result of a system-wide process known as the “acute-phase response”. During the acute-phase 
response, an array of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin 
(IL)-1β and IL-6, are released, primarily by macrophages [12] to enhance insulin resistance directly in 
adipocytes, muscle and hepatic cells [10], resulting in disruption of insulin homeostasis and impaired 
glucose tolerance [13]. Increased levels of pro-inflammatory cytokines lead to hepatic production and 
secretion of acute-phase proteins such as C-reactive protein (CRP), plasminogen activator inhibitor-1 
(PAI-1), serum amyloid-A, α1-acid glycoprotein, fibrinogen, and haptoglobin. These proteins, collec-
tively known as inflammatory markers, appear in the metabolic syndrome and early stages of T2DM, 
and their circulating levels increase as the disease progresses [14]. Indeed, many studies have docu-
mented a relationship between these inflammatory markers and T2DM (for review, see [15]).
Nutritional interventions aimed at reducing systemic inflammation could lead to improved insulin 
sensitivity and delayed disease onset. Adequate physiologic status of anti-inflammatory nutrients has 
been associated with reduced levels of pro-inflammatory cytokines and risk of T2DM [15]. In parti-
cular, vitamin D may improve insulin sensitivity and promote β-cell survival by down-regulating the 
generation and effects of pro-inflammatory cytokines [15,16]. In this respect, epidemiological studies 
suggest that adequate vitamin D status may help prevent the development of T2DM, whereas vitamin 
D deficiency can be associated with T2DM risk [17]. Supplementation with vitamin D may, therefore, 
have a significant public health potential in the general population, particularly in sub-populations 
known to have a high prevalence of vitamin D deficiency. By attenuating inflammation, vitamin D 
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may improve insulin resistance and subsequently prevent or delay the onset of T2DM. The concept 
has been reported, for example, when the modifying effect of vitamin D was examined on the associa-
tions between T2DM and variants of the peroxisome proliferator-activated receptor δ (PPARδ), a gene 
known to predispose to diabetes risk [18]. Elucidating the association between inflammatory markers 
and early stages of T2DM, on the one hand, and the role of vitamin D on modifying this relationship, 
on the other hand, may allow evaluating the use of inflammatory networks in early disease risk predic-
tion. Understanding this interrelationship may also facilitate the characterization of biomarkers (e.g., 
genome-based, proteomics or metabolomics) associated with vitamin D intake.
The present article was undertaken in an attempt to evaluate the relationship between vitamin D, in-
flammation and the risk of T2DM and how to employ this association in developing public health 
approaches for disease early risk prediction and prevention.
Vitamin D metabolism, synthesis, and serum levels
Humans obtain vitamin D through the production of cholecalciferol (vitamin D3) in the epidermis af-
ter ultraviolet irradiation of 7-dehydrocholesterol, and by the absorption of cholecalciferol or its plant 
equivalent (ergocalciferol) from the intestine after intake of vitamin D-rich foods [19]. Cholecalciferol 
is hydroxylated in the liver by the 25-hydroxylase (CYP2R1) to 25(OH)D, which is the major circu-
lating form of vitamin D [19]. In the kidney, 1α-hydroxylase (CYP27B1) then hydroxylates 25(OH)D 
to 1α,25(OH)2D, that is considered a steroid hormone. This active form of the vitamin, via binding to 
vitamin D receptor (VDR), influences the transcriptional regulation of an array of genes and activates 
numerous signal transduction pathways [19]. Moreover, the 1α,25(OH)2D maintains calcium homeo-
stasis by increasing calcium absorption by the intestinal mucosa, decreasing calcium excretion by the 
kidney, and promoting bone resorption via parathyroid hormone (PTH) when serum calcium falls to 
suboptimal levels [20].
Reduced sun exposure, either due to living in latitudes with seasonal shortages of UV radiation (e.g., 
in the Northern hemisphere) or due to extensive body coverage by clothes (e.g., in many countries 
of the Middle East), often translates into difficulties maintaining an adequate vitamin D status and a 
need to obtain this micronutrient orally, e.g., via supplementation [21]. The elderly, certain ethnocul-
tural groups, and individuals with malabsorption diseases are at risk of becoming vitamin D deficient 
[22,23]. In addition, recent genome-wide association studies suggest that common genetic variations, 
e.g, in CYP2R1, may also affect vitamin D status [24-26]. Dietary factors such as fish liver oil, fatty 
fish, including sardines and salmon, egg yolks and fortified milk are important nutritional sources of 
vitamin D [27]. Until very recently, the accepted adequate intake (AI) of vitamin D, which maintains 
serum levels preventing osteomalacia and rickets and based on the absence of sufficient exposure to 
sunlight, was 5 µg/day (200 IU) (as cholecalciferol) for adults, 10 µg/day (400 IU) for people aged 51-70 
years, and 15 µg/day (600 IU) for those aged 71 years and older [28,29]. The tolerable upper intake level 
(UL) was set at 50 µg/day (2000 IU), based on preventing the development of hypercalcemia. However, 
very recently the Institute of Medicine (IOM) of the US National Academy of Sciences has released 
new daily recommended intakes for vitamin D that reflect an increased understanding of the role of 
vitamin D in a number of physiological processes aside from bone metabolism. The new recommended 
dietary allowance (RDA) for individuals younger than 71 years is 600 IU/day, with an increased RDA 
of 800 IU/day for those who are 71 or older. Furthermore, the UL has been doubled to a maximum of 
4,000 IU/day for adults [30]. The primary concern with consuming a greater amount of vitamin D is 
the potential vitamin D toxicity. However, the amount of vitamin D required to produce toxic effects 
(in individuals with no vitamin D hypersensitivity) was suggested to be equivalent to chronically con-
suming 40,000 IU/day [31].
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Vitamin D status is assessed by measuring 25(OH)D and serum levels > 50 nmol/l (> 20 ng/ml) tradi-
tionally have been considered adequate, although increasing evidence strongly suggests that concen-
trations > 75 nmol/l (> 30 ng/ml) are necessary for optimal health [9,28,32]. Vitamin D deficiency is 
defined as serum levels of 25(OH)D < 27.5 nmol/l [33], whereas concentrations > 375 nmol/l are thou-
ght to be toxic [27]. Prevalence of vitamin D deficiency may be higher among subjects of non-Caucasian 
origin [33], due to a decreased rate of ultraviolet radiation absorption by dark skin that results in dimi-
nished vitamin D production [34]. Indeed, we have shown recently that the average serum 25(OH)D 
concentration in individuals with dark skin color (East Asians and South Asians) is 1.5-fold lower than 
that in Caucasians [23].
Vitamin D, inflammation, and T2DM
Vitamin D homeostasis has been linked to conditions such as neuromuscular function, cancer, autoim-
mune diseases, atherosclerosis, CVD, and diabetes. A number of prospective studies have demonstra-
ted an association between high level of inflammation and the development of T2DM [15].
The identification of the vitamin D responsive element (VDRE) in the insulin receptor gene promoter 
(INSR) suggests that 1α,25(OH)2D may influence insulin sensitivity via the transcriptional up-regula-
tion of the INSR [35]. The CYP27B1, which hydroxylates 25(OH)D into 1α,25(OH)2D, was originally 
thought to be present only in renal tissue. However, more recently CYP27B1 was identified in extra-
renal tissues including pancreatic β-cells, which suggests that it may be required for their function [36]. 
The presence of VDRs and vitamin D binding protein (VDBP) in pancreatic β-cells has initiated studies 
demonstrating a relationship between single nucleotide polymorphisms (SNPs) in the genes regulating 
VDR, VDBP and glucose intolerance, and insulin secretion [37-39]. The 1α,25(OH)2D may be required 
for insulin synthesis [40] and may influence its secretion by increasing the expression of calbindin-
D28K in β-cells [41]. Calbindin-D28K has an integral role in regulating intracellular calcium levels of 
β-cells, thus facilitating insulin exocytosis, a calcium-dependent process [41].
In addition to its actions on β-cell function, vitamin D may play a role in T2DM through its potent im-
munomodulatory functions [42-44]. As reviewed recently by our group [15,16], one of the hallmarks 
of T2DM is systemic low-grade inflammation, which is characterized by increased serum levels of pro-
inflammatory cytokines and acute phase reactants. In vitro, 1α,25(OH)2D protects human islets that 
are incubated with pro-inflammatory cytokines from apoptosis [45] and modulates the production of 
the immunostimulatory cytokine IL-12 and the immunosuppressive cytokine IL-10 [46]. Furthermore, 
VDRs are present in most types of immune cells, thus suggesting a role of vitamin D in the immuni-
ty [47]. Additionally, vitamin D supplementation has been shown to reduce inflammatory cytokines 
such as IL-6 and TNF-α, which play a critical role in mediating insulin resistance [48]. These effects of 
vitamin D on cytokines and cytokine synthesis is due to its interaction with VDREs in the promoter 
region of cytokine-encoding genes that downregulates the transcriptional activities of cytokine genes 
and attenuates the synthesis of the corresponding proteins [49]. Vitamin D also deactivates the nuclear 
receptor kappa B (NFκB), which transcriptionally regulates the pro-inflammatory cytokine genes [50]. 
Downregulating the NFκB, and the downstream cytokine genes, it promotes β-cell survival and impro-
ves insulin secretion [49].
Vitamin D deficiency has been linked to T2DM, because circulating levels of 25(OH)D were lower in 
patients than in controls [51,52]. In normoglycemic subjects, 25(OH)D was inversely associated with 
post-prandial plasma glucose, fasting insulin and insulin resistance (defined as homeostatic model 
assessment of insulin resistance – HOMA-IR) [53]. Data from the Third National Health and Nutri-
tion Examination Survey (NHANES III) showed that serum 25(OH)D was inversely associated with 
T2DM and HOMA-IR [54]. We have also reported an inverse association between vitamin D serum 
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levels and HOMA-IR in a population of non-diabetic adults [23]. This inverse association suggests 
that 25(OH)D may play a role in decreasing insulin resistance upon sufficiency. A more recent cross-
sectional study conducted in non-diabetic individuals noted an inverse association between plasma 
25(OH)D and fasting plasma glucose, insulin concentration and HOMA-IR and a positive association 
with the insulin sensitivity index (ISI). In this study, separating subjects into tertiles based on their 
serum 25(OH)D concentration showed that those in the highest tertile (64 nmol/l) had significantly 
lower fasting plasma glucose, fasting plasma insulin and insulin resistance than those in the lowest 
tertile (30 nmol/l) [55]. Indeed, this inverse relationship between vitamin D serum levels and the 
risk of T2DM has been recently addressed from the perspective of the role of this micronutrient (and 
others) in disease intervention [56]. To further substantiate the role of vitamin D in T2DM risk, we 
have also reported that increasing plasma vitamin D level by 10 nmol/l can reduce predisposition to 
T2DM by 14% in a population of healthy adults [23]. Moreover, a higher prevalence of severe vitamin 
D deficiency (< 14 nmol/l) was also observed among diabetic women than healthy controls (39% in 
T2DM vs. 25% in controls) [52]. A study assessing joint vitamin D and calcium intake showed that 
individuals with vitamin D (> 800 IU/day) and calcium (> 1200 mg/day) intake had a 33% lower risk 
of T2DM vs. those who had a vitamin D at < 400 IU/day and calcium at < 600 mg/d [57]. Three years 
of calcium and vitamin D supplementation improved fasting glucose in those with impaired glycemia 
and resulted in a smaller increase in insulin resistance (HOMA-IR) vs. the placebo group [42].
Genetic variation, vitamin D status, 
and inflammatory biomarkers
As mentioned above, there is evidence in favor of a relationship between vitamin D status and pre-
disposition to T2DM, which may be a result of the immunomodulatory and anti-inflammatory pro-
perties of vitamin D. However, the association remains inconsistent and this may reflect confounding 
factors, such as genetic variation affecting the individual responses to vitamin D. The role of common 
genetic variants on vitamin D status has recently begun to be elucidated [24-26]. A meta-analysis of 
genome wide association studies (GWAS) combined results from ~4,500 individuals of European an-
cestry and found significant associations between 25(OH)D concentrations and SNPs in the following 
genetic loci: GC (the gene coding for VDBP), NADSYN1 (encoding nicotinamide adenine dinucleotide 
synthetase), which is in high linkage disequilibrium with a SNP in DHCR7 (encoding 7-dehydrocho-
lesterol reductase, which synthesizes cholesterol from 7-dehydrocholesterol), and CYP2R1 (encoding 
cytochrome P450, family 2, subfamily R, polypeptide 1, a C-25 hydroxylase that converts cholecalci-
ferol to 1α,25(OH)2D) [26]. Similar results were obtained in another meta-analysis of GWAS studies, 
which evaluated serum levels of 25(OH)D and genetic variation in a pooled sample of cohorts con-
sisting of ~34,000 individuals of European origin [25]. A recent candidate gene study examined the 
relationship between common genetic variants of GC and the response of serum levels of 25(OH)D 
to vitamin D supplementation [24]. This group found that a common functional variant of this gene, 
T436K (rs4588, c.1307C> A) predicted differences in response of 25(OH)D levels to supplementation. 
These studies indicate that genetic variants in loci involved in cholesterol synthesis, hydroxylation and 
vitamin D transport may play a role in determining vitamin D status. Furthermore, we have shown 
recently that SNPs in the innate immunity-related inflammatory pathway influence the risk of T2DM 
and that this effect can be mitigated by vitamin D [58]. Although traditional technologies allowed 
for examining the associations between one or a few biomarkers and specific outcomes of interest, 
current advances in proteomics and metabolomics have made it possible to simultaneously determine 
the circulating concentrations of multiple proteins and metabolites, respectively. Apparently, therefore, 
genes along the vitamin D metabolic pathway and action and those along the innate immunity-related 
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inflammation can interact to influence the preventive efficacy of vitamin D on T2DM. Employing such 
a multiplexed approach in relation to vitamin D and inflammation would allow for assessing its effects 
on multiple biomarkers simultaneously. This assessment may also permit to develop an “omics”-based 
signature to distinguish responders to vitamin D intake from non-responders to whom alternative 
preventive measures can be introduced.
Vitamin D in the prevention of T2DM: clinical trials
To date, few clinical trials have assessed the effects of vitamin D supplementation on glycemia, insulin 
resistance, and the progression and complications of T2DM have yielded inconsistent results. In one 
study, diabetic women supplemented with 1332 IU/d for one month increased first phase insulin secre-
tion (FPIS) and second phase insulin secretion (SPIS) by 34% and 20%, respectively [59]. FPIS plays an 
integral role in reducing post-prandial glucose levels [59]. These findings suggest that vitamin D defi-
ciency may decrease insulin secretion and that supplementation may help restore insulin secretion, 
thus ameliorating T2DM. We summarized a number of observational longitudinal cohort studies and 
randomized controlled trials evaluating the effect of vitamin D on diabetes and its related risk factors 
in Table I.
A randomized, placebo-controlled study examined the effect of vitamin D (400 IU/day) and calcium 
(1000 mg/day) (Ca+D) on the risk of T2DM in non-diabetic, postmenopausal women [60]. At the 
7-year follow-up, there were 2291 newly diagnosed cases of T2DM; however, no difference between 
the Ca+D and placebo groups was observed (Table I). Although this study did not show a significant 
negative association between Ca+D and developing T2DM, it is important to note that the amount 
of vitamin D given was low compared to that used in previous studies (≥ 2000 IU/day) [42]. More 
recently, a randomized placebo-controlled trial conducted by von Hurst et al. examined the effect of 
vitamin D (4000 IU/day) on insulin sensitivity and secretion in a cohort of insulin resistant, vitamin 
D deficient women [62]. After six months of vitamin D supplementation, serum 25(OH)D increased 
from 21 to 75 nmol/l. Significant improvements in insulin sensitivity and a decrease in fasting glucose 
and insulin resistance were also observed in the treated group vs. placebo [62]. However, this study 
only included women, and the measure of insulin sensitivity used was HOMA, which is calculated 
from fasting glucose and insulin. HOMA is used widely in epidemiological studies because it is cheap 
and easy to obtain; however, it is a measure of liver insulin sensitivity rather than of muscle or whole 
body insulin sensitivity. The study showed that vitamin D supplementation had no effect on fasting 
serum glucose (Table I). This is important because, clinically, diabetes and other forms of dysglycemia 
are identified by measuring fasting and/or post-prandial blood glucose. Thus, it is important to know 
whether vitamin D can influence fasting or post-prandial blood glucose. To date, very few clinical trials 
have been conducted to examine this question and have analyzed the effects of physiological dosages 
(50-4000 IU/day) on markers of T2DM. However, few have examined the effects of administering 
supra-physiological doses of vitamin D. One study conducted in healthy, centrally-obese, non-diabetic 
men examined the effect of three oral doses of 120,000 IU of vitamin D or placebo over a period of six 
weeks on HOMA-IR, insulin sensitivity, OGIS and insulin secretion [63] (Table I). The study found 
that supplementation improved OGIS compared to placebo although this effect was on the board of 
being significant [63]. However, no changes were observed in the other outcome measures despite the 
increase in serum 25(OH)D. The data in Table I permitted us to conclude that vitamin D serum levels 
of more than 30 ng/ml (> 73.8 nmol/l, i.e., the recent cut-off for vitamin D sufficiency of 75 nmol/l) 
can, indeed, be associated with significant improvement in a number of metabolic phenotypes related 
to T2DM. This observation suggests that a public health strategy based on increasing serum levels of 





Vitamin D  
(intake/serum level3 or 
supplementation)
Duration  
of follow-up or 
treatment (yrs)9
RR, OR, or HR  
(95% CI, ptrend) or 
improved outcome (p)10
Ref.
Observational longitudinal cohort studies
M 1628 57 Level: 30 vs. 10 ng/ml 22 0.49 (0.15-1.64; 0.06) [64]
1948 53 Level: 31 vs. 9 ng/ml 17 0.17 (0.05-0.52; < 0.001) [64]
25,877 57 Intake: 720 vs 188 IU/d 5 0.96 (0.74-1.23; 0.35) [65]
F 10,066 52 Intake: > 511 vs. < 159 IU/d 9 0.73 (0.54-0.99; 0.02) [66]
83,779 46 Intake: > 800 vs. < 200 IU/d 20 0.87 (0.69-1.09; 0.67) [57]
1699 57 Level: 25 vs. 9 ng/ml 22 0.91 (0.37-2.23; 0.66) [64]
2228 55 Level: 25 vs. 8 ng/ml 17 1.45 (0.58-3.62; 0.83) [64]
33,919 57 Intake: 696 vs. 192 IU/d 5 0.88 (0.67-1.16; 0.67) [65]
32,826 46 Level: 33 vs. 14 ng/ml 14 0.52 (0.33-0.83; 0.008) [67]
M:F = 1:0.8 2956 60 Level: 22 vs. 17 ng/ml 7 0.60 (0.37-0.97; 0.03) [68]
Randomized controlled trials
M 71 43 D3: 8571 IU/d
4 6 (wks) OGIS (0.055)
HOMA-IR (0.95)
[61]
F 151 49 D3: 2000 IU/d (Ca
++ 500 mg/d)
1(OH)D3: 0.25 mcg/d (+Ca
++)
2 FPG (0.97) [69]
33,951 62 D3: 400 IU/d (Ca
++ 1000 mg/d) 7 HR (0.95) [60]
1637 65 D3: 400 IU/d (Ca
++ 1000 mg/d) 6 FPG (0.32) [60]
1457 65 D3: 400 IU/d (Ca
++ 1000 mg/d) 6 FPG (0.79) [60]
81 42 D3: 4000 IU/d 0.5 FPG (0.82)
HOMA-IR (0.02)
[62]
M:F = 1:1.6 222 71 D3: 700 IU/d (Ca
++ 500 mg/d) 3 FPG (0.55) [42]
M:F = ~1:1 92 71 D3: 700 IU/d (Ca
++ 500 mg/d) 3 FPG (0.042) [42]
M:F = ~1:1 34 64 D3: 1785 IU/d (Ca
++ 500 mg/d)5 8 (wks) HbA1c (0.74)
HOMA-IR (0.72)
[70]
M:F = 1:1.6 5292 77 D3: 800 IU/d (Ca
++ 1000 mg/d) 2-5 HR (0.16) [71]
M:F = 1:1.3 200 48 D3: 3332 IU/d 1 HbA1c (0.96)
FPG (0.39)
[72]
M:F = 1:1 32 56 D3: 5714 IU/d
6 0.5 FPG (0.43)
HOMA-IR (0.58)
[73]
M:F = 1:1.8 438 38 D3: 5714 IU/d (Ca
++ 500 mg/d)7
D3: 2857 IU/d (Ca
++ 500 mg/d)8
1 NSC [74]
Table I. Summary of the observational longitudinal cohort studies and randomized controlled trials 
evaluating the effect of vitamin D on diabetes and its related risk factors1
1 Cross-sectional or retrospective case-control studies and randomized trials of a period less than one month 
were excluded
2 About half the studied cohort in each trial is placebo. In those studies where there are two treatments, the 
number of subjects is divided to approximately 3 equal groups to include the placebo treatment
3 “Levels” refers to the serum vitamin D levels as 25(OH)D, whereas “intake” refers to dietary intake
4-6 The treatments are the daily equivalent doses of: 4 120,000 IU/d x 3 times; 5 100,000 IU/d given once; and 6 
40,000 IU/wk
7,8 The treatments represent the daily equivalence to 40,000 and 20,000 IU/wk, respectively
9 Duration of follow-up for the observational longitudinal cohort studies whereas duration for treatment is for 
the randomized controlled trials
10 Significant values are presented in bold text
d = day; FPG = fasting plasma glucose; HbA1C = glycated hemoglobin; HOMA-IR = homeostasis model of 
assessment-insulin resistance; HR = hazard ratio; OGIS = oral glucose insulin sensitivity; NSC = no significant 
changes; OR = odds ratio; RR = relative risk.
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inflammation can interact to influence the preventive efficacy of vitamin D on T2DM. Employing such 
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tion (FPIS) and second phase insulin secretion (SPIS) by 34% and 20%, respectively [59]. FPIS plays an 
integral role in reducing post-prandial glucose levels [59]. These findings suggest that vitamin D defi-
ciency may decrease insulin secretion and that supplementation may help restore insulin secretion, 
thus ameliorating T2DM. We summarized a number of observational longitudinal cohort studies and 
randomized controlled trials evaluating the effect of vitamin D on diabetes and its related risk factors 
in Table I.
A randomized, placebo-controlled study examined the effect of vitamin D (400 IU/day) and calcium 
(1000 mg/day) (Ca+D) on the risk of T2DM in non-diabetic, postmenopausal women [60]. At the 
7-year follow-up, there were 2291 newly diagnosed cases of T2DM; however, no difference between 
the Ca+D and placebo groups was observed (Table I). Although this study did not show a significant 
negative association between Ca+D and developing T2DM, it is important to note that the amount 
of vitamin D given was low compared to that used in previous studies (≥ 2000 IU/day) [42]. More 
recently, a randomized placebo-controlled trial conducted by von Hurst et al. examined the effect of 
vitamin D (4000 IU/day) on insulin sensitivity and secretion in a cohort of insulin resistant, vitamin 
D deficient women [62]. After six months of vitamin D supplementation, serum 25(OH)D increased 
from 21 to 75 nmol/l. Significant improvements in insulin sensitivity and a decrease in fasting glucose 
and insulin resistance were also observed in the treated group vs. placebo [62]. However, this study 
only included women, and the measure of insulin sensitivity used was HOMA, which is calculated 
from fasting glucose and insulin. HOMA is used widely in epidemiological studies because it is cheap 
and easy to obtain; however, it is a measure of liver insulin sensitivity rather than of muscle or whole 
body insulin sensitivity. The study showed that vitamin D supplementation had no effect on fasting 
serum glucose (Table I). This is important because, clinically, diabetes and other forms of dysglycemia 
are identified by measuring fasting and/or post-prandial blood glucose. Thus, it is important to know 
whether vitamin D can influence fasting or post-prandial blood glucose. To date, very few clinical trials 
have been conducted to examine this question and have analyzed the effects of physiological dosages 
(50-4000 IU/day) on markers of T2DM. However, few have examined the effects of administering 
supra-physiological doses of vitamin D. One study conducted in healthy, centrally-obese, non-diabetic 
men examined the effect of three oral doses of 120,000 IU of vitamin D or placebo over a period of six 
weeks on HOMA-IR, insulin sensitivity, OGIS and insulin secretion [63] (Table I). The study found 
that supplementation improved OGIS compared to placebo although this effect was on the board of 
being significant [63]. However, no changes were observed in the other outcome measures despite the 
increase in serum 25(OH)D. The data in Table I permitted us to conclude that vitamin D serum levels 
of more than 30 ng/ml (> 73.8 nmol/l, i.e., the recent cut-off for vitamin D sufficiency of 75 nmol/l) 
can, indeed, be associated with significant improvement in a number of metabolic phenotypes related 
to T2DM. This observation suggests that a public health strategy based on increasing serum levels of 





Vitamin D  
(intake/serum level3 or 
supplementation)
Duration  
of follow-up or 
treatment (yrs)9
RR, OR, or HR  
(95% CI, ptrend) or 
improved outcome (p)10
Ref.
Observational longitudinal cohort studies
M 1628 57 Level: 30 vs. 10 ng/ml 22 0.49 (0.15-1.64; 0.06) [64]
1948 53 Level: 31 vs. 9 ng/ml 17 0.17 (0.05-0.52; < 0.001) [64]
25,877 57 Intake: 720 vs 188 IU/d 5 0.96 (0.74-1.23; 0.35) [65]
F 10,066 52 Intake: > 511 vs. < 159 IU/d 9 0.73 (0.54-0.99; 0.02) [66]
83,779 46 Intake: > 800 vs. < 200 IU/d 20 0.87 (0.69-1.09; 0.67) [57]
1699 57 Level: 25 vs. 9 ng/ml 22 0.91 (0.37-2.23; 0.66) [64]
2228 55 Level: 25 vs. 8 ng/ml 17 1.45 (0.58-3.62; 0.83) [64]
33,919 57 Intake: 696 vs. 192 IU/d 5 0.88 (0.67-1.16; 0.67) [65]
32,826 46 Level: 33 vs. 14 ng/ml 14 0.52 (0.33-0.83; 0.008) [67]
M:F = 1:0.8 2956 60 Level: 22 vs. 17 ng/ml 7 0.60 (0.37-0.97; 0.03) [68]
Randomized controlled trials
M 71 43 D3: 8571 IU/d
4 6 (wks) OGIS (0.055)
HOMA-IR (0.95)
[61]
F 151 49 D3: 2000 IU/d (Ca
++ 500 mg/d)
1(OH)D3: 0.25 mcg/d (+Ca
++)
2 FPG (0.97) [69]
33,951 62 D3: 400 IU/d (Ca
++ 1000 mg/d) 7 HR (0.95) [60]
1637 65 D3: 400 IU/d (Ca
++ 1000 mg/d) 6 FPG (0.32) [60]
1457 65 D3: 400 IU/d (Ca
++ 1000 mg/d) 6 FPG (0.79) [60]
81 42 D3: 4000 IU/d 0.5 FPG (0.82)
HOMA-IR (0.02)
[62]
M:F = 1:1.6 222 71 D3: 700 IU/d (Ca
++ 500 mg/d) 3 FPG (0.55) [42]
M:F = ~1:1 92 71 D3: 700 IU/d (Ca
++ 500 mg/d) 3 FPG (0.042) [42]
M:F = ~1:1 34 64 D3: 1785 IU/d (Ca
++ 500 mg/d)5 8 (wks) HbA1c (0.74)
HOMA-IR (0.72)
[70]
M:F = 1:1.6 5292 77 D3: 800 IU/d (Ca
++ 1000 mg/d) 2-5 HR (0.16) [71]
M:F = 1:1.3 200 48 D3: 3332 IU/d 1 HbA1c (0.96)
FPG (0.39)
[72]
M:F = 1:1 32 56 D3: 5714 IU/d
6 0.5 FPG (0.43)
HOMA-IR (0.58)
[73]
M:F = 1:1.8 438 38 D3: 5714 IU/d (Ca
++ 500 mg/d)7
D3: 2857 IU/d (Ca
++ 500 mg/d)8
1 NSC [74]
Table I. Summary of the observational longitudinal cohort studies and randomized controlled trials 
evaluating the effect of vitamin D on diabetes and its related risk factors1
1 Cross-sectional or retrospective case-control studies and randomized trials of a period less than one month 
were excluded
2 About half the studied cohort in each trial is placebo. In those studies where there are two treatments, the 
number of subjects is divided to approximately 3 equal groups to include the placebo treatment
3 “Levels” refers to the serum vitamin D levels as 25(OH)D, whereas “intake” refers to dietary intake
4-6 The treatments are the daily equivalent doses of: 4 120,000 IU/d x 3 times; 5 100,000 IU/d given once; and 6 
40,000 IU/wk
7,8 The treatments represent the daily equivalence to 40,000 and 20,000 IU/wk, respectively
9 Duration of follow-up for the observational longitudinal cohort studies whereas duration for treatment is for 
the randomized controlled trials
10 Significant values are presented in bold text
d = day; FPG = fasting plasma glucose; HbA1C = glycated hemoglobin; HOMA-IR = homeostasis model of 
assessment-insulin resistance; HR = hazard ratio; OGIS = oral glucose insulin sensitivity; NSC = no significant 
changes; OR = odds ratio; RR = relative risk.
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proposition is supported by our recent findings that increasing plasma vitamin D level by 10 nmol/l 
was significantly inversely associated with HOMA-IR (p = 0.006) and results in 14% lower probability 
of having metabolic syndrome, a major risk factor in T2DM (CI = 0.75-0.99) [23]. To our knowledge, 
there are no long-term studies (≥ 6 months) examining the effects of higher vitamin D doses (≥ 4000 
IU/day) on 2 hr post-challenge glucose, insulin sensitivity and secretion, disposition index, “omics”-
based inflammatory markers and markers of hepatic steatosis in pre-diabetic subjects with vitamin D 
deficiency. Therefore, we are currently conducting a long-term clinical trial across Canada to evaluate 
the efficacy of 2000 IU/d vitamin D supplementation (for 6 months) on insulin homeostasis and serum 
glucose levels to evaluate its effect on the risk of T2DM.
Conclusion
The current state of knowledge warrants further study into the extent of association between inflamma-
tory markers and early stages of T2DM, on the one hand, and the role of vitamin D in modifying this 
relationship, on the other hand. Such an approach is critical to comprehensively evaluate the possible 
application of inflammatory network assessment in disease surveillance. The development of such evi-
dence-based biomarkers can be introduced as a public health genomic-based measure for T2DM early 
prediction, in addition to other traditional risk factors such as family history or physical examination. 
In this respect, inflammatory biomarkers may permit capturing the etiological function of (and inte-
raction between) genetic constitution and environmental risk modifiers in the T2DM pathogenesis. 
Furthermore, a major benefit of introducing inflammatory markers into public health settings stems 
from their potential to facilitate developing a novel class of agents which attenuate low-grade inflam-
mation prior to the clinical onset of T2DM and to be employed in disease prevention. However, before 
applying these biomarkers in public health, protocols for their assessment should be standardized and 
laboratory reference intervals need to be applied in decision-making processes.
Employing this set of biomarkers in evaluating responses to prevention may necessitate examining the 
dynamic interaction between genetic and dietary modifiers in the etiology of T2DM. It seems likely 
that vitamin D can modify the genotype–phenotype association within the innate immune respon-
se. This proposition may elucidate the mechanisms by which vitamin D and other nutritional factors 
–which can be introduced into the general population and susceptible subpopulations – prevent or 
delay disease development. Recently, we demonstrated that vitamin D status can provide an excellent 
marker of “good” health, including positive associations with young age, normal body weight and a 
healthy lifestyle [23,75]. The potential role of vitamin D supplementation in combating the inflamma-
tory cytokines and improving impaired glycemia and insulin resistance, holds enormous public health 
implications. Evaluating the efficacy of vitamin D in this prospect may demand a series of pilot clinical 
studies to be further explored, developed, and optimized, that include developing tools to accurately 
and reproducibly measure the circulating/tissue levels of potential biomarkers in order to relate them 
to clinical outcome. The impact of vitamin D on T2DM incidence may then be assessed through a seri-
es of pilot population-based studies: firstly, to determine the feasibility and effectiveness of this proto-
col; second, to validate and evaluate the strategy and ensure replication of results; and, third, to monitor 
the outcome to quantify the overall preventive response in comparison (and combination) with the 
current preventive approaches for T2DM such as lifestyle changes, exercise, and dietary intervention.
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